Arcadia Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated July 2, 2024, details significant executive leadership changes at Arcadia Biosciences, Inc. The report covers events occurring between July 2 and July 5, 2024, involving the departure of the former CEO and the appointment of new leadership.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Severance Payment: $288,077 (cash) to the departing CEO, subject to withholdings.
- New CFO Base Salary: $212,063 annually.
- Other Benefits: Twelve months of accelerated stock option vesting and health insurance coverage through February 2025 for the departing CEO.
Material Changes
The primary material change is the restructuring of the company's executive team:
- Departure: Stanley Jacot, Jr. resigned as President, Chief Executive Officer, and Director effective July 2, 2024.
- CEO Appointment: Thomas J. Schaefer, previously the Chief Financial Officer, was appointed President and CEO effective July 5, 2024.
- CFO Appointment: Mark Kawakami, previously Vice President of Finance, was appointed Chief Financial Officer effective July 5, 2024.
Outlook, Risks, and Management Commentary
The filing does not provide updated financial guidance, market outlook, or specific risk factors beyond the standard disclosure of the Separation Agreement. The transition of leadership is presented as a completed event with effective dates set for July 5, 2024. The Separation Agreement includes a general release of claims and customary confidentiality provisions.
Key Facts for Investor Verification
- Verify the effective date of the leadership transition (July 5, 2024) and the immediate impact on strategic direction.
- Review the full Separation Agreement (Exhibit 10.1) for details on the $288,077 severance and accelerated vesting terms.
- Confirm the background and tenure of the new CEO (Thomas J. Schaefer) and CFO (Mark Kawakami), both of whom are internal promotions.
- Monitor subsequent filings for any changes in corporate strategy or financial guidance resulting from the leadership change.